Should I buy or sell Acumen Pharmaceuticals stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABOS shares. View ABOS analyst ratings or view top-rated stocks .

What is Acumen Pharmaceuticals' stock price target for 2024?

5 brokerages have issued 12 month target prices for Acumen Pharmaceuticals' stock. Their ABOS share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 247.0% from the stock's current price. View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts .

How have ABOS shares performed in 2024?

Acumen Pharmaceuticals' stock was trading at $3.84 on January 1st, 2024. Since then, ABOS shares have decreased by 8.1% and is now trading at $3.53. View the best growth stocks for 2024 here .

Are investors shorting Acumen Pharmaceuticals?

Acumen Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,240,000 shares, an increase of 21.6% from the March 15th total of 1,020,000 shares. Based on an average trading volume of 369,100 shares, the days-to-cover ratio is currently 3.4 days. Currently, 2.9% of the company's stock are short sold. View Acumen Pharmaceuticals' Short Interest .

When is Acumen Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ABOS earnings forecast .

How were Acumen Pharmaceuticals' earnings last quarter?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its earnings results on Monday, November, 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same quarter in the previous year, the company posted ($0.26) earnings per share.

When did Acumen Pharmaceuticals IPO?

Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share.

How do I buy shares of Acumen Pharmaceuticals?

Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ABOS

Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ABOS Stock Alerts

$3.53

-0.21 (-5.61%)

(As of 04/15/2024 ET)

Compare

Today's Range: $3.53
▼
$3.77
50-Day Range: $3.02
▼
$4.64
52-Week Range: $1.81
▼
$11.31

Volume: 214,885 shs
Average Volume: 383,515 shs
Market Capitalization: $212.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.25

Get Acumen Pharmaceuticals alerts:

Acumen Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 247.0% Upside
$12.25 Price Target
Short Interest: Healthy
2.88% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 3 Articles This Week
Insider Trading: Selling Shares
$110,136 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.22) to ($1.47) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

404th out of 928 stocks

Biological Products, Except Diagnostic Industry

58th out of 153 stocks

3.5

Analyst's Opinion

Consensus Rating
Acumen Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Acumen Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
2.88% of the float of Acumen Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Acumen Pharmaceuticals has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Acumen Pharmaceuticals has recently increased by 21.57%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Acumen Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Acumen Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ABOS.

3.3

News and Social Media Coverage

News Sentiment
Acumen Pharmaceuticals has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Acumen Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
8 people have searched for ABOS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Acumen Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $110,136.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Acumen Pharmaceuticals is held by insiders.
Percentage Held by Institutions
71.01% of the stock of Acumen Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Acumen Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.47) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Acumen Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Acumen Pharmaceuticals is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Acumen Pharmaceuticals has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

Click here to see the details because there’s a lot of money at stake.

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

ABOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ABOS Stock News Headlines

April 13, 2024 | americanbankingnews.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Up 21.6% in March

April 4, 2024 | finance.yahoo.com

Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

April 4, 2024 | markets.businessinsider.com

Acumen Pharma Partners Lonza To Advance Sabirnetug For Alzheimer's Disease Treatment

April 4, 2024 | finance.yahoo.com

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

April 4, 2024 | globenewswire.com

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

April 4, 2024 | msn.com

Sames Auto Group partners with Driscoll Children’s Hospital

March 27, 2024 | msn.com

Acumen Pharmaceuticals files for $200M mixed shelf offering

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Acumen Pharmaceuticals on Promising Alzheimer’s Drug Trial Outcomes

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Acumen Pharmaceuticals Amid Promising Alzheimer’s Treatment Development and Attractive Valuation

March 27, 2024 | finance.yahoo.com

Q4 2023 Acumen Pharmaceuticals Inc Earnings Call

March 27, 2024 | finance.yahoo.com

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript

March 26, 2024 | globenewswire.com

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

March 19, 2024 | globenewswire.com

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

March 12, 2024 | globenewswire.com

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

March 8, 2024 | finance.yahoo.com

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

February 24, 2024 | finance.yahoo.com

Institutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)

February 21, 2024 | finance.yahoo.com

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

February 21, 2024 | globenewswire.com

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

February 17, 2024 | finance.yahoo.com

ABOS Mar 2024 2.500 put

February 7, 2024 | finance.yahoo.com

Buy Alert: 3 Healthcare Stocks Sitting in the Sweet Spot

February 1, 2024 | finance.yahoo.com

3 Healthcare Stocks to Buy as the Sector Benefits from the Aging Boom

February 1, 2024 | finance.yahoo.com

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

January 8, 2024 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Acumen Pharmaceuticals (ABOS)

January 4, 2024 | finance.yahoo.com

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 13, 2023 | msn.com

Deutsche Bank Initiates Coverage of Acumen Pharmaceuticals (ABOS) with Buy Recommendation

See More Headlines

Receive ABOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acumen Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 4/15/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:ABOS
CUSIP: N/A
CIK: 1576885
Web: www.acumenpharm.com
Phone: 434-297-1000
Fax: N/A
Employees: 39
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $12.25
High Stock Price Target: $15.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +247.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.40%
Return on Assets: -21.78%

Debt

Debt-to-Equity Ratio: 0.11
Current Ratio: 19.01
Quick Ratio: 19.01

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.61 per share
Price / Book: 0.77

Miscellaneous

Outstanding Shares: 60,080,000
Free Float: 55,574,000
Market Cap: $212.08 million
Optionable: Optionable
Beta: 0.09

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Mr. Daniel J. O'Connell M.B.A. (Age 53)
CEO & Director
Comp: $901.2k
Mr. Matt Zuga
CFO & Chief Business Officer
Mr. Derek M. Meisner Esq. (Age 53)
J.D., Chief Legal Officer & Corporate Secretary
Comp: $240.17k
Dr. James Doherty Ph.D. (Age 56)
President & Chief Development Officer
Dr. Grant A. Krafft Ph.D.
Co-Founder
Dr. Caleb E. Finch Ph.D.
Co-Founder
Dr. William L. Klein Ph.D.
Co-Founder
Mr. Russell Barton M.S. (Age 65)
Chief Operating Officer
Comp: $223.68k
Ms. Kelly Carranza
Vice President, Finance & Accounting and Corporate Controller
Ms. Alex Braun M.B.A.
VP & Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ABOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Acumen Pharmaceuticals stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Acumen Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABOS shares.
View ABOS analyst ratings or view top-rated stocks.
What is Acumen Pharmaceuticals' stock price target for 2024?: 5 brokerages have issued 12 month target prices for Acumen Pharmaceuticals' stock. Their ABOS share price targets range from $8.00 to $15.00. On average, they expect the company's stock price to reach $12.25 in the next year. This suggests a possible upside of 247.0% from the stock's current price.
View analysts price targets for ABOS or view top-rated stocks among Wall Street analysts.
How have ABOS shares performed in 2024?: Acumen Pharmaceuticals' stock was trading at $3.84 on January 1st, 2024. Since then, ABOS shares have decreased by 8.1% and is now trading at $3.53.
View the best growth stocks for 2024 here.
Are investors shorting Acumen Pharmaceuticals?: Acumen Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,240,000 shares, an increase of 21.6% from the March 15th total of 1,020,000 shares. Based on an average trading volume of 369,100 shares, the days-to-cover ratio is currently 3.4 days. Currently, 2.9% of the company's stock are short sold.
View Acumen Pharmaceuticals' Short Interest.

When is Acumen Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ABOS earnings forecast.
How were Acumen Pharmaceuticals' earnings last quarter?: Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) posted its earnings results on Monday, November, 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.07. During the same quarter in the previous year, the company posted ($0.26) earnings per share.
When did Acumen Pharmaceuticals IPO?: Acumen Pharmaceuticals (ABOS) raised $125 million in an initial public offering (IPO) on Thursday, July 1st 2021. The company issued 8,333,333 shares at a price of $14.00-$16.00 per share.
How do I buy shares of Acumen Pharmaceuticals?: Shares of ABOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABOS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Acumen Pharmaceuticals (ABOS) Stock Price, News & Analysis

Acumen Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

ABOS Stock Price History

ABOS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ABOS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™